Economic evaluation of ulinastatin vs octreotide in treatment of acute pancreatitis

Key words: 
• ulinastatin /
• sandostain /
• pancreatitis /
• acute /
• cost-minimization analysis

Abstract: Objective To evaluate the economic effectiveness of domestic ulinastatin and sandostain in the treatment of acute pancreatitis. Methods 41 cases with acute pancreatitis were divided into 2 groups according to the therapeutic drug: the ulinastatin group and the sandostain group. The two groups were compared by cost-minimization analysis of pharmacoeconomics. Results There is no significant difference in clinical therapeutic effect between two groups, but the cost of the sandostain group is much higher than the ulinastatin group. Conclusion The cost of domestic ulinastatin is minimization.